The fund raising could also be done through issue of equity shares or any other eligible securities, through one or more permissible modes including but not limited to qualified institutions placement, rights issue, preferential issue and further public offer etc., in one or more tranches.

The company’s board will also consider a proposal for investment in Biocon Biologics (BBL), an unlisted material subsidiary of the company, by way of purchase or acquisition of securities from shareholders of BBL, for cash and/or consideration other than cash through issuance and allotment of fully paid-up equity shares of the company on a preferential allotment basis through private placement.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025.

The scrip fell 4.68% to currently trade at Rs 390.95 on the BSE.